 |
|
|
| |
Longer-term (96-week) Efficacy and Safety of Switching to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF) in Women
|
| |
| |
Reported by Jules Levin
Mexico City IAS 2019 July 21-24
Cissy Kityo,1 Debbie Hagins,2 Ellen Koenig,3 Anchelee Avihingsanon,4
Ploenchan Chetchotisakd,5 Khuanchai Supparatpinyo,6 Natalya Gankina,7 Vadim Pokrovsky,8 Evgenly Voronin,9 Jeffrey L. Stephens,10 Edwin DeJesus,11 Hui Wang,12 Rima Acosta,12
Diana Brainard,12 Hal Martin,12 Tariro Makadzange12
1Joint Clinical Research Centre, Kampala, Uganda; 2Georgia Department of Public Health, Coastal Health District, Chatham CARE Center, Savannah, GA; 3Zona Universitaria, Instituto Dominicano de Estudios Virologicos, Santo Domingo, Dominion Republic; 4The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 5Srinagarind Hospital, Khon Kaen, Thailand; 6Chiang Mai University, Chiang Mai, Thailand; 7Krasnoyarsk Territorial Center for Prevention and Control of AIDS and Infectious Diseases, Krasnoyarsk, Russia; 8Center for Prevention and Control of AIDS, Moscow, Russia; 9Federal Budgetary Institution “Republican Clinical Infectious Hospital” of the Ministry of Health of the Russian Federation, Saint-Petersburg; 10Mercer University School of Medicine, Macon, GA; 11Orlando Immunology Center, Orlando, FL; 12Gilead Sciences Inc., Foster City, CA
|
| |
|
|
|
|
|
